On January 31, 2016, the tenth and final subject received their last blinded experimental treatment session in our Israeli Phase 2 study of MDMA-assisted psychotherapy for PTSD. In addition to being the final blinded experimental session in this study, it was also the final blinded experimental session in Phase 2 of MAPS’ plan to develop MDMA-assisted psychotherapy into a legal treatment for PTSD. Led by Principal Investigator Moshe Kotler, M.D., this Phase 2 study has treated 10 subjects with chronic, treatment-resistant PTSD from any cause. Once the final evaluations are complete, we will gather data for inclusion in an international meta-analysis of the safety and efficacy of MDMA-assisted psychotherapy for the treatment of PTSD.
